In 2017, the total incident population of Peripheral T-Cell Lymphoma (PTCL) in 7MM was 16,298. In 2017, with 6,110 cases the United States accounted for the highest incident population among the seven major markets. PTCL accounts for about 10-15% of all Non-Hodgkin Lymphomas worldwide.
The market size of Peripheral T-Cell Lymphoma (PTCL) in 7MM was found to be USD 815.38 Million in 2017, which is expected to increase during the forecast period 2017-2030.
Use of combination therapies, upcoming novel therapies in the pipeline for the treatment of PTCL, and an upsurge in research and development are some of the key factors expected to drive the PTCL market forward in the coming years.
The key players in the Peripheral T-Cell Lymphoma (PTCL) market includes Eisai, Verastem Oncology, Affimed, Aileron Therapeutics, Solasia Pharma, Genor Biopharma, Bristol-Myers Squibb, AB Science, CerRx Inc., Celgene, Pfizer, Novartis/Incyte, Kura Oncology, BeiGene, Merck, PharmaMar, HUYA Bioscience International, Innate Pharma, Sorrento Therapeutics, Astex Pharmaceuticals, Otsuka Pharmaceutical and others.
For more detailed information on Peripheral T-Cell Lymphoma (PTCL) Market, visit:
https://www.delveinsight.com/report-store/peripheral-t-cell-lymphoma-ptcl-market